In response to the opioid crisis, Vivera has invented ZICOH™, a dose-controlled, electronic drug delivery device that will change the way prescription medications with a higher risk of abuse are prescribed, dispensed, and tracked. The Company invites the criticized parties most for their role in the opioid crisis, including prescription drug manufacturers, wholesalers, distributors, and pharmacies, to be a part of the solution by partnering and investing in ZICOH.
CLICK HERE TO LEARN MORE ABOUT ZICOH™
Vivera has long understood that to tackle the opioid crisis, we first need to prevent addiction from occurring in the first place. About 25 percent of patients who are prescribed opiates for chronic pain misuse them, and about ten percent of patients taking opioids for chronic pain develop an opioid use disorder. Ultimately, opioids are killing over 100 Americans every day and are a factor in 7 out of every ten overdose deaths.
“Nearly everyone has been directly affected by or knows someone who has been affected by addiction,” said
ZICOH will utilize a secure database integrated with AI to form a unique software architecture and advanced patented technology, making it the first device of its kind to enable effective communication through the drug supply chain, from drug manufacturers to wholesalers, distributors, pharmacists, providers, physicians, caregivers, and patients. The device can be programmed to dispense the medication dosage amount, type, and frequency to patients according to the health care provider’s orders and delivery schedule. Each of its features helps ensure patient compliance and patient follow-up, consequentially reducing the risk of addiction and overdose.
“Our ZICOH device technology along with its elaborate, secure communication network and ecosystem has been in development and perfection for the past five years with the major goal of saving lives and providing a viable solution to the ever-increasing opioid crisis,” said Mehdi Hatamian , Ph.D., Chief Scientific Advisor for Vivera. “The billions of dollars in damages, regardless of how large the number before the ‘b’ is, will never ever bring back the lives that were lost; it is time to act to prevent future names added to the lost-forever list.”
“Vivera’s ZICOH medical device is an important breakthrough and an essential clinical tool to address the opioid crisis,” said
Opioids are estimated to have taken the lives of over one million people. According to preliminary data released by the
According to the lawsuits, AmerisourceBergen, Cardinal Health, McKesson, Johnson & Johnson, and Purdue Pharma played a significant role in the current state of the opioid epidemic.
Vivera is offering these parties, along with insurance companies, pharmacies, drug manufacturers, and other stakeholders, an opportunity to be part of a solution that has the potential to save millions of lives.
“We are at a pivotal moment where it’s time to make a choice. Are you joining our mission to end the opioid crisis, or are you going to continue to be accused of being part of the problem?” CEO asked of Vivera,
For more information, please visit viverapharmaceuticals.com or connect with us on LinkedIn, Facebook, Twitteror Instagram.
View original content to download multimedia: https://www.prnewswire.com/news-releases/will-recent-32-billion-in-opioid-settlements-prevent-addiction-vivera-has-the-answer-301498661.html